DDOOD Stock UPDATES Cerebain Biotech Corp. (DDOOD) 1.6800 08/03/2014
Post# of 273249
Discount Dental Materials announces name change to Cerebain Biotech Corp
M2 - Fri Jun 20, 4:40AM CDT
Discount Dental Materials Inc (OTCBB DOO), announced on Thursday that it has changed its name to Cerebain Biotech Corp.
Discount Dental Materials, Inc. Changes Its Name to Cerebain Biotech Corp.
Business Wire - Thu Jun 19, 8:00AM CDT
Discount Dental Materials, Inc. (OTCBB: DDOOD), announced that it has changed its name to Cerebain Biotech Corp. ("Cerebain" or "the Company" .
Cerebain Biotech engages consultant for representation in the PRC
M2 - Wed Jan 22, 4:07AM CST
Cerebain Biotech Corp, a subsidiary of Discount Dental Materials Inc (OTCBB DOO), a discoverer of products for the treatment of Alzheimer's disease utilising Omentum, announced on Tuesday the engagement of John Ballard to represent the company in The People's Republic of China.
Cerebain Biotech Corp. Announces Engagement of Consultant for Representation in China
Business Wire - Tue Jan 21, 8:00AM CST
Cerebain Biotech Corp. ("Cerebain" or "the Company" , a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO), announced today that it has engaged John Ballard to represent the Company in The People's Republic of China for the purpose of Clinical Testing of the Company's Medical Device for the treatment of Alzheimer's Disease utilizing the Omentum. The Consultant will serve as the intermediary in China to determine and finalize any required local approvals and establish essential partnerships with Doctors and Medical Facilities necessary for this testing once the Company's prototype is completed. The medical device is being developed by Cerebain Biotech Corp as a potential new approach for the treatment for patients suffering from Alzheimer's and Dementia.
Cerebain Biotech Corp. Announces Commencement of Discussions for Representation in Poland
Business Wire - Wed Sep 11, 8:00AM CDT
Cerebain Biotech Corp. ("Cerebain" or "the Company" , a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO) announced today that it has commenced discussions pertaining to representation of the Company in Poland for the purpose of Clinical Testing of the Company's Medical Device for the treatment of Alzheimer's Disease utilizing the Omentum. The purpose of these discussions are to engage consultants to determine and finalize any required local approvals and establish essential partnerships with Doctors and Medical Facilities necessary for this testing once the Company's prototype is completed. The medical device is being developed by Cerebain Biotech Corp as a potential new approach to the treatment for patients suffering from Alzheimer's and Dementia.
Cerebain Biotech Releases Updated Photo of Its First Prototype of the Company's Medical Device Product for Treatment of Alzheimer's
Business Wire - Fri Aug 23, 8:00AM CDT
Cerebain Biotech Corp. ("Cerebain" or "the Company" , a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO), announced that medical device product development company, Sonos Models, Inc. ("Sonos" , has provided additional photo of the first prototype of the Company's medical device solution for the treatment of Alzheimer's disease utilizing the Omentum.
OTC Daily Alert Stock Watch - Discount Dental Materials Inc (OTCQB: DDOO)
WorldStockWire - Wed Aug 21, 1:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Cerebain Biotech Releases Initial Photos of Its First Prototype of the Company's Medical Device Product for Treatment of Alzheimer's
Business Wire - Mon Aug 12, 5:00AM CDT
Cerebain Biotech Corp. ("Cerebain" or "the Company" , a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO), announced that medical device product development company, Sonos Models, Inc. ("Sonos" , has provided photos of the first prototype of the Company's medical device solution for the treatment of Alzheimer's disease utilizing the Omentum.
Cerebain Biotech Corp. to Hold Conference Call
Business Wire - Sun Jun 30, 1:26PM CDT
Cerebain Biotech Corp. ("Cerebain" or "the Company" , a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO) announced today it intends to hold a conference call on July 1st at 3:30 p.m. EST. The purpose of the call is to permit Dr. Surinder Saini, Chairman of the Company's Scientific Advisory Board, an opportunity to provide the genesis of and thought processes surrounding the Company's efforts to develop the world's first medical device specifically designed for the treatment of Alzheimer's disease utilizing the Omentum. Investors and Analysts may join the conference call by dialing 712-432-9998, and entering access code 126307#.
Cerebain Biotech Provides Medical Device Update
Business Wire - Thu Jun 27, 8:46AM CDT
Cerebain Biotech Corp. ("Cerebain" or "the Company" , a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO), announced that medical device product development company, Sonos Models, Inc. ("Sonos" , is set to complete the first prototypes of its medical device solution during the company's first fiscal quarter, which begins July 1, 2013.
Cerebain Biotech Corp. Announces Engagement of IDC Consulting for Representation in Uzbekistan
Business Wire - Mon Jun 24, 2:43PM CDT
Cerebain Biotech Corp. ("Cerebain" or "the Company" , a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO), announced today that it has engaged IDC Consulting to represent the Company in Uzbekistan for the purpose of Clinical Testing of the Company's Medical Device for the treatment of Alzheimer's Disease utilizing the Omentum. IDC Consulting will serve as the intermediary in Uzbekistan to determine and finalize any required local approvals and establish essential partnerships with Doctors and Medical Facilities necessary for this testing once the Company's prototype is completed. The medical device is being developed by Cerebain Biotech Corp. as a potential new approach to the treatment for patients suffering from Alzheimer's and Dementia.
Cerebain Biotech Corp. Appoints Dr. Saini Chairman of Its Scientific Advisory Board
Business Wire - Mon Jun 17, 3:09PM CDT
Cerebain Biotech Corp. ("Cerebain" or "the Company" , a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO) announced today the appointment of Dr. Surinder Saini as Chairman of its Scientific Advisory Board. The advisory board provides key clinical insight into the company's efforts to develop and commercialize a novel approach to the treatment for patients suffering from Alzheimer's disease. Dr. Saini is the lead scientist behind the development of the world's first medical device specifically designed for the treatment of Alzheimer's disease utilizing the Omentum.
Cerebain Biotech Corp. Announces Information Available Through S&P's Corporation Records Program
Marketwire - Tue May 07, 8:01AM CDT
Cerebain Biotech Corp. ("Cerebain" or "the Company" , a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO) announced today that its company information is available via Standard & Poor's Corporation Records Listing Program. As part of the program, a full description of Discount Dental Materials, Inc. will be published in the Daily News Section of Standard & Poor's Corporation Records, a recognized securities manual for secondary trading in up to 38 States under the Blue Sky Laws. Standard & Poor's Corporation Records is available in print, CD-ROM, and via the web at www.netadvantage.standardandpoors.com as well as through numerous electronic vendors.